DongKoo Bio&Pharma Co. Ltd (006620) — Capital Reinvestment Ratio
Latest as of September 2025:
3.06x
DongKoo Bio&Pharma Co. Ltd (006620) has a Capital Reinvestment Ratio of 3.06x as of September 2025, meaning it reinvests 3% of its operating cash flow (₩1.20 Billion) in capital expenditures (₩3.66 Billion). See cash generation quality of DongKoo Bio&Pharma Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
3.06x
Capex / Operating Cash Flow
Operating Cash Flow
₩1.20 Billion
KRW
Capital Expenditures
₩3.66 Billion
KRW
Data as of
Sep 2025
Most recent filing
DongKoo Bio&Pharma Co. Ltd Capital Reinvestment Ratio (2015–2024)
This chart tracks DongKoo Bio&Pharma Co. Ltd's Capital Reinvestment Ratio across 9 annual periods.
Annual Capital Reinvestment Ratio for DongKoo Bio&Pharma Co. Ltd (2015–2024)
Year-by-year Capital Reinvestment Ratio for DongKoo Bio&Pharma Co. Ltd from 2015 to 2024. For live market cap and broader valuation context, see DongKoo Bio&Pharma Co. Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.47x | ₩17.34 Billion | ₩25.46 Billion | ▼ -67.0% |
| 2023 | 4.45x | ₩3.59 Billion | ₩15.97 Billion | ▲ +576.2% |
| 2022 | 0.66x | ₩16.82 Billion | ₩11.08 Billion | ▲ +176.3% |
| 2021 | 0.24x | ₩17.90 Billion | ₩4.27 Billion | ▼ -66.1% |
| 2020 | 0.70x | ₩7.49 Billion | ₩5.27 Billion | ▼ -18.7% |
| 2019 | 0.86x | ₩10.14 Billion | ₩8.77 Billion | ▲ +914.5% |
| 2017 | 0.09x | ₩9.51 Billion | ₩810.51 Million | ▼ -83.6% |
| 2016 | 0.52x | ₩12.59 Billion | ₩6.55 Billion | ▲ +55.9% |
| 2015 | 0.33x | ₩6.93 Billion | ₩2.32 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow